Journal ID (nlm-ta): Neurooncol Adv
Journal ID (iso-abbrev): Neurooncol Adv
Journal ID (publisher-id): noa
Title:
Neuro-Oncology Advances
Publisher:
Oxford University Press
(US
)
ISSN
(Electronic):
2632-2498
Publication date Collection: Jan-Dec 2022
Publication date
(Electronic):
06
September
2022
Publication date PMC-release: 06
September
2022
Volume: 4
Issue: 1
Electronic Location Identifier: vdac141
Affiliations
Rosalind and Morris Goodman Cancer Institute, McGill University , Montreal, Québec, Canada
McGill University Health Centre, Department of Diagnostic Radiology, McGill University , Montreal, Québec, Canada
McGill University Health Centre, Department of Diagnostic Radiology, McGill University , Montreal, Québec, Canada
Rosalind and Morris Goodman Cancer Institute, McGill University , Montreal, Québec, Canada
Montreal Neurological Institute-Hospital, McGill University , Montreal, Québec, Canada
Department of Computer Science, University of Calgary , Calgary, Alberta, Canada
Rosalind and Morris Goodman Cancer Institute, McGill University , Montreal, Québec, Canada
Author notes
Corresponding Authors: Matthew Dankner, PhD, Goodman Cancer Research Institute McGill University, 1160
Pine Ave West, Rm. 508, Montreal, QC H3A 1A3, Canada (
matthew.dankner@
123456mail.mcgill.ca
)
Farhad Maleki, PhD, Department of Computer, Science, University of Calgary, 2500 University
Dr. NW, Calgary, AB T2N 1N4, Canada (
farhad.maleki1@
123456ucalgary.ca
)
Author information
Article
Publisher ID:
vdac141
DOI: 10.1093/noajnl/vdac141
PMC ID: 9583687
PubMed ID: 36284932
SO-VID: 8974934b-64dd-4655-a29b-db6f7ec933e1
Copyright © © The Author(s) 2022. Published by Oxford University Press, the Society for Neuro-Oncology
and the European Association of Neuro-Oncology.
License:
This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (
https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium,
provided the original work is properly cited.
Funded by:
Canadian Institute of Health Research;
Funded by:
Vanier Canada Graduate Scholarships;
Funded by:
Spark Grants on the Application of Disruptive Technologies in Cancer Prevention;
Funded by:
Early Detection;
Funded by:
Canadian Cancer Society Research Institute, DOI 10.13039/501100000015;
Funded by:
Canadian Institutes of Health Research—Institute of Cancer Research;
Funded by:
Brain Canada Foundation, DOI 10.13039/100009408;
Award ID: #707078/CIHR
Award ID: #707078
Funded by:
Health Canada, DOI 10.13039/501100000008;
Funded by:
Canada Brain Research Fund;
Funded by:
Government of Canada, DOI 10.13039/501100000023;
Funded by:
Brain Canada, DOI 10.13039/100009408;